This Author published in this journals
All Journal Pharmacy Reports
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Famotidine for COVID-19 Chrisnanda, Anang Agung; Saputro, Anjar Hermadi
Pharmacy Reports Vol. 3 No. 1 (2023): Pharmacy Reports
Publisher : Indonesian Young Scientist Group and UPN Veteran Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51511/pr.10

Abstract

Famotidine has emerged as a candidate for COVID-19 treatment, with various studies investigating its impact on the virus. These studies have reported encouraging results, suggesting that famotidine might contribute to fighting COVID-19 by potentially blocking histamine release, TMPRSS, and fortifying glycocalyx. Clinical trials aimed at assessing the effectiveness of famotidine in patients with COVID-19 have observed that it contributed to quicker alleviation of symptoms and reduction in inflammation, without compromising the body's immunity against SARS-CoV-2. However, in the case of patients with severe illness, famotidine's use did not significantly enhance survival rates. Although further investigation is necessary, famotidine has shown promise in alleviating symptoms and reducing inflammation in COVID-19 cases.